{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:58:44Z","timestamp":1791406724622,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T00:00:00Z","timestamp":1351123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2407-12-496","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T14:14:06Z","timestamp":1351174446000},"source":"Crossref","is-referenced-by-count":55,"title":["PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours"],"prefix":"10.1186","volume":"12","author":[{"given":"Mark J","family":"McKeage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa J","family":"Melink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Simon","family":"Tchekmedyian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,25]]},"reference":[{"issue":"6","key":"3385_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Canc. 2011, 11 (6): 393-410. 10.1038\/nrc3064.","journal-title":"Nat Rev Canc"},{"issue":"17","key":"3385_CR2","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-11-1182","volume":"71","author":"K Toustrup","year":"2011","unstructured":"Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J: Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Canc Res. 2011, 71 (17): 5923-5931. 10.1158\/0008-5472.CAN-11-1182.","journal-title":"Canc Res"},{"issue":"4","key":"3385_CR3","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","volume":"70","author":"CP Guise","year":"2010","unstructured":"Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al: The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Canc Res. 2010, 70 (4): 1573-1584. 10.1158\/0008-5472.CAN-09-3237.","journal-title":"Canc Res"},{"issue":"9","key":"3385_CR4","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-08-4023","volume":"69","author":"RS Singleton","year":"2009","unstructured":"Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR: DNA cross-links in human tumor cells exposed to the prodrug PR-104A: Relationships to hypoxia, bioreductive metabolism and cytotoxicity. Canc Res. 2009, 69 (9): 3884-3891. 10.1158\/0008-5472.CAN-08-4023.","journal-title":"Canc Res"},{"issue":"13","key":"3385_CR5","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1158\/1078-0432.CCR-07-0478","volume":"13","author":"AV Patterson","year":"2007","unstructured":"Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al: Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Canc Res. 2007, 13 (13): 3922-3932. 10.1158\/1078-0432.CCR-07-0478.","journal-title":"Clin Canc Res"},{"issue":"1","key":"3385_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/mol.111.073759","volume":"81","author":"CP Guise","year":"2012","unstructured":"Guise CP, Abbattista MR, Tipparaju SR, Lambie NK, Su JC, Li D, Wilson WR, Dachs GU, Patterson AV: Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol Pharmacol. 2012, 81 (1): 31-40. 10.1124\/mol.111.073759.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"3385_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00280-009-1188-1","volume":"65","author":"MB Jameson","year":"2010","unstructured":"Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR: A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Canc Chemother Pharmacol. 2010, 65 (4): 791-801. 10.1007\/s00280-009-1188-1.","journal-title":"Canc Chemother Pharmacol"},{"issue":"1","key":"3385_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/1471-2407-11-432","volume":"11","author":"MJ McKeage","year":"2011","unstructured":"McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011, 11 (1): 432-10.1186\/1471-2407-11-432.","journal-title":"BMC Cancer"},{"issue":"3","key":"3385_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","volume":"54","author":"S Noble","year":"1997","unstructured":"Noble S, Goa KL: Gemcitabine - a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997, 54 (3): 447-472. 10.2165\/00003495-199754030-00009.","journal-title":"Drugs"},{"key":"3385_CR10","first-page":"08807","volume-title":"Taxotere (docetaxel) full prescribing information","author":"US Sanofi-Aventis","year":"2011","unstructured":"Sanofi-Aventis US: Taxotere (docetaxel) full prescribing information. 2011, Bridgewater NJ, Bridgewater NJ, 08807- http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020449s064lbl.pdf ,"},{"issue":"2","key":"3385_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1010662413174","volume":"19","author":"SH Jang","year":"2001","unstructured":"Jang SH, Wientjes MG, Au JLS: Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs. 2001, 19 (2): 113-123. 10.1023\/A:1010662413174.","journal-title":"Invest New Drugs"},{"issue":"18","key":"3385_CR12","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1158\/0008-5472.CAN-04-0986","volume":"64","author":"LA Huxham","year":"2004","unstructured":"Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI: Microregional effects of gemcitabine in HCT-116 xenografts. Canc Res. 2004, 64 (18): 6537-6541. 10.1158\/0008-5472.CAN-04-0986.","journal-title":"Canc Res"},{"issue":"3","key":"3385_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0167-8140(97)00186-2","volume":"46","author":"JD Chapman","year":"1998","unstructured":"Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Gerald GE: Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 1998, 46 (3): 229-237. 10.1016\/S0167-8140(97)00186-2.","journal-title":"Radiother Oncol"},{"issue":"3","key":"3385_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid Tumors. J Natl Canc Inst. 2000, 92 (3): 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Canc Inst"},{"issue":"27","key":"3385_CR15","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1016\/j.jchromb.2009.08.009","volume":"877","author":"Y Gu","year":"2009","unstructured":"Gu Y, Wilson WR: Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877 (27): 3181-3186. 10.1016\/j.jchromb.2009.08.009.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1\u20132","key":"3385_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jlcr.1147","volume":"50","author":"GJ Atwell","year":"2007","unstructured":"Atwell GJ, Denny WA: Synthesis of H-3- and H-2(4)-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl) anilino)ethyl methanesulfonate (PR-104). J Label Compd Radiopharm. 2007, 50 (1\u20132): 7-12.","journal-title":"J Label Compd Radiopharm"},{"issue":"3","key":"3385_CR17","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1124\/dmd.109.030973","volume":"38","author":"Y Gu","year":"2010","unstructured":"Gu Y, Atwell GJ, Wilson WR: Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans. Drug Metab Dispos. 2010, 38 (3): 498-508. 10.1124\/dmd.109.030973.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3385_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.111.180703","volume":"337","author":"Y Gu","year":"2011","unstructured":"Gu Y, Tingle MD, Wilson WR: Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-Glucuronosyltransferases, and implications for therapy. J Pharmacol Exp Ther. 2011, 337 (3): 692-702. 10.1124\/jpet.111.180703.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3385_CR19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","volume":"17","author":"DP Petrylak","year":"1999","unstructured":"Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999, 17 (3): 958-967.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3385_CR20","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-0842-03","volume":"10","author":"SD Baker","year":"2004","unstructured":"Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA: Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Canc Res. 2004, 10 (6): 1976-1983. 10.1158\/1078-0432.CCR-0842-03.","journal-title":"Clin Canc Res"},{"issue":"5","key":"3385_CR21","first-page":"1037","volume":"53","author":"JM Extra","year":"1993","unstructured":"Extra JM, Rousseau F, Bruno R, Clavel M, Lebail N, Marty M: Phase-I and pharmacokinetic study of Taxotere(RP-56976, NSC-628503) given as a short intravenous-infusion. Canc Res. 1993, 53 (5): 1037-1042.","journal-title":"Canc Res"},{"issue":"3","key":"3385_CR22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al: A phase-I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991, 9 (3): 491-498.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3385_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1023\/A:1013133415945","volume":"12","author":"S Fogli","year":"2001","unstructured":"Fogli S, Danesi R, Braud FD, Pas TD, Curigliano G, Giovannetti E, Del Tacca M: Drug distribution and pharmacokinetic\/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001, 12 (11): 1553-1559. 10.1023\/A:1013133415945.","journal-title":"Ann Oncol"},{"issue":"3","key":"3385_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","volume":"6","author":"AG Hall","year":"1992","unstructured":"Hall AG, Tilby MJ: Mechanisms of action of, and modes of resistance to, alkylating-agents used in the treatment of hematological malignancies. Blood Rev. 1992, 6 (3): 163-173. 10.1016\/0268-960X(92)90028-O.","journal-title":"Blood Rev"},{"issue":"5","key":"3385_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00280-010-1412-z","volume":"67","author":"K Patel","year":"2011","unstructured":"Patel K, Choy SSF, Hicks KO, Melink TJ, Holford NHG, Wilson WR: A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Canc Chemother Pharmacol. 2011, 67 (5): 1145-1155. 10.1007\/s00280-010-1412-z.","journal-title":"Canc Chemother Pharmacol"},{"issue":"2","key":"3385_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2001.19.2.535","volume":"19","author":"D Rischin","year":"2001","unstructured":"Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001, 19 (2): 535-542.","journal-title":"J Clin Oncol"},{"key":"3385_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdq203","volume":"21","author":"M Borad","year":"2010","unstructured":"Borad M, Mita A, Infante J, Chiorean EG, Vlahovic G, Armstrong A, Traynor AM, Schelman W, Langmuir V, Eng C: Complete phase Ib study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P). Ann Oncol. 2010, 21: 172-172. 10.1093\/annonc\/mdq203.","journal-title":"Ann Oncol"},{"key":"3385_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0923-7534(19)66473-2","volume":"23","author":"D Ryan","year":"2012","unstructured":"Ryan D, Reddy S, Bahary N, Uronis H, Sigal DS, Cohn A, Schelman WR, Chiorean EG, Rosen PJ, Ulrich B, et al: Phase II study of gemcitabine + TH-302 vs gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer. Ann Oncol. 2012, 23: 8-8.","journal-title":"Ann Oncol"},{"issue":"9","key":"3385_CR29","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-10-3425","volume":"17","author":"GJ Weiss","year":"2011","unstructured":"Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, et al: Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. Clin Canc Res. 2011, 17 (9): 2997-3004. 10.1158\/1078-0432.CCR-10-3425.","journal-title":"Clin Canc Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-496\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T03:52:12Z","timestamp":1594785132000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3385"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-496","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,25]]},"article-number":"496"}}